Seizure exacerbation and developmental regression with carbamazepine

Canadian Journal of Neurological Sciences

Volumn 25, Issue 4, 1998, Pages 287-294

  Prasad, A N ^a,d   Stefanelli, M ^b,c   Nagarajan, L ^d,e  

^a Ihè Discipline of Pediatrics

^b New Janeway Childrens Health and Rehabilitation Centre   (Canada)

^c Discipline of Medicine

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e Princess Margaret Hospital Perth   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; GABAPENTIN; LAMOTRIGINE; VALPROIC ACID;

ARTICLE; CHILD; CLINICAL ARTICLE; DETERIORATION; ELECTROENCEPHALOGRAM; EPILEPSY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEUROLOGIC EXAMINATION; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; SEIZURE;

EID: 0031771689     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100034296     Document Type: Article

References (29)

1. Levy L, Fenichel G. Diphenylhydantoin activated seizures. Neurology 1965; 15: 716-722.
2. Vallarta JM, Bell DB, Reichert A. Progressive encephalopathy due to chronic hydantoin intoxication. Am J Dis Child 1974; 128: 27-34.
3. Wilder BJ, Rangel R. Carbamazepine efficacy in adults with partial and generalized tonic- clonic seizures. Epilepsia 1987; 28 Suppl 3: S25-S28.
4. Dodson WE. Carbamazepine efficacy and utilization in children. Epilepsia 1987; 28 Suppl 3: S17-S24.
5. Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of Carbamazepine therapy in children. Neurology 1983; 33:1487-1489.
6. Snead OC 3rd, Hosey LC. Exacerbation of seizures in children by Carbamazepine. N Engl J Med 1985; 313: 916-921.
7. Loiseau P. Do antiepileptic drugs exacerbate seizures? Epilepsia 1998; 39: 2-4.
8. de Suva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, Carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-713.
9. Johnsen S, Tarby T, Sidell A. Carbamezepine induced seizures. Ann Neurol 1984; 16: 392-393.
10. Liporace JD, Sperling MR, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994; 35: 1026-1028.
11. Horn CS, Ater SB, Hurst DL. Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr Neurol 1986; 2: 340-345.
12. Marescaux C, Hirsch E, Finck S, et al. Landau-Kleffner syndrome: a pharmacologie study of five cases. Epilepsia 1990; 31: 768777.
13. So EL, Ruggles KH, Cascino GD, Ahmann PA, Weatherford KW. Seizure exacerbation and status epilepticus related to carbamazepine- 10,11-epoxide. Ann Neurol 1994; 35: 743-746.
14. Sachdeo R, Chokroverty S. Enhancement of absence with Tegretol (Abstract). Epilepsia 1985; 26: 534.
15. Callahan DJ, Noetzel MJ. Prolonged absence status epilepticus associated with Carbamazepine therapy, increased intracranial pressure, and transient MRI abnormalities. Neurology 1992; 42: 198-201.
16. Silverstein FS, Parrish MA, Johnston MV. Adverse behavioral reactions in children treated with Carbamazepine (Tegretol). J Pediatr 1982; 101: 785-787.
17. Marjerrison G, Jedlicki SM, Keogh RP, Hrychuk W, Poulakakis GM. Carbamazepine: behavioral, anticonvulsant and EEC effects in chronically-hospitalized epileptics. Dis Nerv Syst 1968; 29:133-136.
18. Pryse-Phillips WE, Jeavons PM. Effect of carbamazepine (Tegretol) on the electroencephalograph and ward behaviour of patients with chronic epilepsy. Epilepsia 1970; 11: 263-273.
19. Rodin EA, Rim CS, Rennick PM. The effects of carbamazepine on patients with psychomotor epilepsy: results of a double-blind study. Epilepsia 1974; 15: 547-561.
20. Jeavons P. Carbamazepine and the EEG. In: Wink C, ed. Tegretol in epilepsy: report of an international clinical symposium. Manchester: C. Nicholls, 1972: 35-39.
21. Wilkus R, Dodrill C, Troupin A. Carbamazepine and the electroencephalogram in epileptics: a double blind study in comparison to phenytoin. Epilepsia 1978; 19: 283-291.
22. Talwar D, Arora MS, Sher PK. EEG changes and seizure exacerbation in young children treated with carbamazepine. Epilepsia 1994; 35:1154-1159.
23. Swinyard E, Woodhead J. Experimental detection, quantification and evaluation of anticonvulsants. In: Woodbury D, Penry J, Pippenger C, eds. Antiepileptic Drugs. New York: Raven Press, 1982: 111-126.
24. Snead OC 3rd. Basic mechanisms of generalized absence seizures. Ann Neurol 1995; 37:146-157.
25. Lortie A, Chiron C, Mumford J, Dulac O. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 1993; 43: S24-S27.
26. Dhuna A, Pascual-Leone A, Talwar D. Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine. Epilepsia 1991; 32: 275-278.
27. Sozuer D, Atakli D, Atay T, Baybas S, Arpaci B. Evaluation of various antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia 1996; 37: 77.
28. Wakai S, Ito N, Sueoka H, et al. Severe myoclonic epilepsy in infancy and carbamazepine [letter]. Eur J Pediatr 1996; 155: 724.
29. Viani F, Romeo A, Viri M, et al. Seizure and EEG patterns in Angelman's syndrome. J Child Neurol 1995; 10:467-471.